An observational study in Cancer of Stomach, Oesophageal Cancer and Gastric Cancer, sponsored by Western Sydney Local Health District. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Western Sydney Local Health District · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Stomach Neoplasms with a site in Australia — 29 open to participants now, 51 under way, 8 of them phase 3. Stomach Neoplasms · Australia.
Among the 110 studies in Stomach Neoplasms with a site in Australia, this one is one of 9 that started in 2023, is one of 2 observational ones, reaches primary completion later than 30 of the 50 other live ones, and was the 73rd registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →29 of the 110 studies in Stomach Neoplasms with a site in Australia are open now. Recruiting first, the newest first:
XYone Therapeutics, Inc · Sites in Australia
Ages 18+
Novartis Pharmaceuticals · Sites in Australia, Japan
Ages 18+
Second Life Therapeutics · Sites in Australia
Ages 18+
Bristol-Myers Squibb · Sites in Australia, United States, Argentina and 17 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Austria and 21 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 44 · Phase 3 28
First in 2003; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 160 across the 107 interventional studies, 750 across the 2 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 110 have an industry lead sponsor. The 10 most frequent:
Western Sydney Local Health District is the lead sponsor of 36 studies on the registry; 18 are open to participants now.
Western Sydney Local Health District has 2 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
18 of the studies in Stomach Neoplasms with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01924819Phase 3Australasian Gastro-Intestinal Trials GroupTrial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma | 2026-12-31 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT06337084Monopar TherapeuticsDiagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | 2026-12 |
| NCT05872295Iksuda Therapeutics Ltd.IKS014 in Advanced Solid Tumors That Express HER2 | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 110 studies in Stomach Neoplasms with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
To collect prospective observational data on patients undergoing ESD, EFTR or STER for UGI neoplastic lesions
Patients referred to tertiary centre for endoscopic resection of gastrointestinal neoplasm
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
UGI neoplastic lesions > 10mm
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm
Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection
Determined based on clear margins in histology review
Time frame: 2 weeks
Safety: intra and post procedural; bleeding; perforation; anaesthetic
Intraprocedural bleeding, clinically significant post-polypectomy bleeding, deep mural injury, post polypectomy coagulation syndrome
Time frame: 30 day
Long term outcomes: recurrent and residual disease
Determined at subsequent procedures
Time frame: 3 years
Endoscopic sessions, procedure time (in minutes) and overall time (in weeks) needed to achieve the primary objectives
Determined after follow up procedure to confirm no recurrence
Time frame: 6 months
Need for more than one endoscopic therapy
Determined after follow up procedures
Time frame: 3 years
Need for surgery
Determined after follow up procedures, histological review
Time frame: 2 months
Post ESD, EFTR, STER defect features
Determined after complete resection
Time frame: 1 day
Patient interviews/questionnaires
Determined after follow up procedures
Time frame: 3 years
Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.
Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 60 months is close to that.
Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Western Sydney Local Health District